Advertisement

EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2

  • Koen Van LaereEmail author
  • Andrea Varrone
  • Jan Booij
  • Thierry Vander Borght
  • Flavio Nobili
  • Özlem L. Kapucu
  • Zuzana Walker
  • Kjell Någren
  • Klaus Tatsch
  • Jacques Darcourt
Guidelines

Abstract

The guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The aims of the guidelines are to assist nuclear medicine practitioners in making recommendations, performing, interpreting and reporting the results of clinical dopamine D2 receptor SPECT or PET studies, and to achieve a high quality standard of dopamine D2 receptor imaging, which will increase the impact of this technique in neurological practice.

The present document is an update of the first guidelines for SPECT using D2 receptor ligands labelled with 123I [1] and was guided by the views of the Society of Nuclear Medicine Brain Imaging Council [2], and the individual experience of experts in European countries. The guidelines intend to present information specifically adapted to European practice. The information provided should be taken in the context of local conditions and regulations.

Keywords

Brain Dopamine D2 receptor SPECT PET Parkinsonism 

Notes

Acknowledgements

The members of the ENC acknowledge the role of the following persons (in alphabetical order) for their advice and contribution to this and the previous guidelines: S. Asenbaum, M. Bardiés, A. Bischof Delaloye, R. Boellaard, P. Bartenstein, A. Catafau, L. Friberg, C. Halldin, M. Nowak Lonsdale, L. Pilowsky, A. Pupi and M. Seppänen, as well as the EANM Dosimetry and Physics Committee.

Disclaimer

These guidelines summarize the views of the Neuroimaging Committee of the EANM and reflect recommendations for which the EANM cannot be held responsible. The recommendations should be taken in the context of good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions. The guidelines have been brought to the attention of the National Societies of Nuclear Medicine.

References

  1. 1.
    Tatsch K, Asenbaum S, Bartenstein P, et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine transporter ligands. Eur J Nucl Med Mol Imaging. 2002;29:BP30–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Society of Nuclear Medicine Brain Imaging Council. Ethical clinical practice of functional brain imaging. J Nucl Med. 1996;37:1256–9.Google Scholar
  3. 3.
    Elsinga PH, Hatano K, Ishiwata K. PET tracers for imaging of the dopaminergic system. Curr Med Chem. 2006;13:2139–53.CrossRefPubMedGoogle Scholar
  4. 4.
    Mukherjee J, Yang ZY, Das MK, Brown T. Fluorinated benzamide neuroleptics – III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol. 1995;22:283–96.CrossRefPubMedGoogle Scholar
  5. 5.
    Schreckenberger M, Hagele S, Siessmeier T, et al. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging. 2004;31:1128–35.CrossRefPubMedGoogle Scholar
  6. 6.
    Farde L, Ehrin E, Eriksson L, et al. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci U S A. 1985;82:3863–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Lindsey KP, Gatley SJ. Applications of clinical dopamine imaging. Neuroimaging Clin N Am. 2006;16:553–73, vii–viiiCrossRefPubMedGoogle Scholar
  8. 8.
    Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology. 2005;64:208–15.PubMedGoogle Scholar
  9. 9.
    Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. Neuroimage. 2004;23:1–16.CrossRefPubMedGoogle Scholar
  10. 10.
    Booij J, Knol RJ. SPECT imaging of the dopaminergic system in (premotor) Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(Suppl 3):S425–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Halldin C, Gulyas B, Langer O, Farde L. Brain radioligands – state of the art and new trends. Q J Nucl Med. 2001;45:139–52.PubMedGoogle Scholar
  12. 12.
    Pinborg LH, Videbaek C, Knudsen GM, et al. Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion. Synapse. 2000;36:322–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Knudsen GM, Karlsborg M, Thomsen G, et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging. 2004;31:1631–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry. 2002;73:517–23.CrossRefPubMedGoogle Scholar
  15. 15.
    Oyanagi C, Katsumi Y, Hanakawa T, et al. Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodobenzofuran single-photon emission computed tomography. J Neuroimaging. 2002;12:316–24.CrossRefPubMedGoogle Scholar
  16. 16.
    Kim YJ, Ichise M, Ballinger JR, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord. 2002;17:303–12.CrossRefPubMedGoogle Scholar
  17. 17.
    Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson’s disease. Brain. 1997;120(Pt 12):2187–95.CrossRefPubMedGoogle Scholar
  18. 18.
    Pirker W, Asenbaum S, Wenger S, et al. Iodine-123-epidepride-SPECT: studies in Parkinson’s disease, multiple system atrophy and Huntington’s disease. J Nucl Med. 1997;38:1711–7.PubMedGoogle Scholar
  19. 19.
    Plotkin M, Amthauer H, Klaffke S, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm. 2005;112:677–92.CrossRefPubMedGoogle Scholar
  20. 20.
    Pani L, Pira L, Marchese G. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur Psychiatry. 2007;22:267–75.CrossRefPubMedGoogle Scholar
  21. 21.
    Scherer J, Tatsch K, Schwarz J, Oertel W, Kirsch MC, Albus M. Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics. Biol Psychiatry. 1994;36:627–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Klemm E, Grunwald F, Kasper S, et al. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Am J Psychiatry. 1996;153:183–90.PubMedGoogle Scholar
  23. 23.
    Ichise M, Toyama H, Fornazzari L, Ballinger JR, Kirsh JC. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington’s disease. J Nucl Med. 1993;34:1274–81.PubMedGoogle Scholar
  24. 24.
    Ginovart N, Lundin A, Farde L, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington’s disease. Brain. 1997;120(Pt 3):503–14.CrossRefPubMedGoogle Scholar
  25. 25.
    Oertel WH, Tatsch K, Schwarz J, et al. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson’s disease. Ann Neurol. 1992;32:743–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Muhr C. Positron emission tomography in acromegaly and other pituitary adenoma patients. Neuroendocrinology. 2006;83:205–10.CrossRefPubMedGoogle Scholar
  27. 27.
    Heiss WD, Herholz K. Brain receptor imaging. J Nucl Med. 2006;47:302–12.PubMedGoogle Scholar
  28. 28.
    Rinne JO, Hietala J, Ruotsalainen U, et al. Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C]raclopride. J Cereb Blood Flow Metab. 1993;13:310–4.PubMedGoogle Scholar
  29. 29.
    Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging. 2007;34:1240–53.CrossRefPubMedGoogle Scholar
  31. 31.
    Popperl G, Radau P, Linke R, Hahn K, Tatsch K. Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism. Nucl Med Commun. 2005;26:39–43.CrossRefPubMedGoogle Scholar
  32. 32.
    Radau PE, Linke R, Slomka PJ, Tatsch K. Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med. 2000;41:220–7.PubMedGoogle Scholar
  33. 33.
    Zubal IG, Early M, Yuan O, Jennings D, Marek K, Seibyl JP. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson’s disease patients. J Nucl Med. 2007;48:857–64.CrossRefPubMedGoogle Scholar
  34. 34.
    Buchert R, Berding G, Wilke F, et al. IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies. Eur J Nucl Med Mol Imaging. 2006;33:1073–83.CrossRefPubMedGoogle Scholar
  35. 35.
    Slifstein M, Hwang DR, Martinez D, et al. Biodistribution and radiation dosimetry of the dopamine D2 ligand 11C-raclopride determined from human whole-body PET. J Nucl Med. 2006;47:313–9.PubMedGoogle Scholar
  36. 36.
    Verhoeff NP, Sokole EB, Stabin M, et al. Dosimetry of iodine-123 iodobenzamide in healthy volunteers. Eur J Nucl Med. 1993;20:747–52.PubMedGoogle Scholar
  37. 37.
    Votaw JR, Ansari MS, Mason NS, et al. Dosimetry of iodine-123-epidepride: a dopamine D2 receptor ligand. J Nucl Med. 1995;36:1316–21.PubMedGoogle Scholar

Copyright information

© EANM 2009

Authors and Affiliations

  • Koen Van Laere
    • 1
    Email author
  • Andrea Varrone
    • 2
  • Jan Booij
    • 3
  • Thierry Vander Borght
    • 4
  • Flavio Nobili
    • 5
  • Özlem L. Kapucu
    • 6
  • Zuzana Walker
    • 7
  • Kjell Någren
    • 8
  • Klaus Tatsch
    • 9
  • Jacques Darcourt
    • 10
  1. 1.Division of Nuclear MedicineUniversity Hospital LeuvenLeuvenBelgium
  2. 2.Department of Clinical Neuroscience, Psychiatry SectionKarolinska InstituteStockholmSweden
  3. 3.Department of Nuclear Medicine, Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands
  4. 4.Nuclear Medicine DivisionUniversité Catholique de Louvain, Mont-Godinne Medical CenterYvoirBelgium
  5. 5.Clinical Neurophysiology Unit, San Martino HospitalUniversity of GenoaGenovaItaly
  6. 6.Department of Nuclear MedicineGazi UniversityAnkaraTurkey
  7. 7.Psychiatry, Department of Mental Health SciencesUniversity College LondonLondonUK
  8. 8.RigshospitaletCopenhagen University HospitalCopenhagenDenmark
  9. 9.Department of Nuclear MedicineMunicipal Hospital of Karlsruhe IncKarlsruheGermany
  10. 10.Nuclear Medicine DivisionCentre Antoine Lacassagne and University Hospital, Université de Nice Sophia AntipolisNiceFrance

Personalised recommendations